IDEXX Laboratories, Inc. IDXX NDXSPX
Company Overview
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Why Investors Should Care
Generates a return on equity of 72.9%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 61.8%.
Net profit has compounded at 14.8% per year over the last five years.
Maintains a net profit margin of 24.6%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $4.30B (+10.4% YoY); net profit $1.06B.
- Trailing 12 Months Year-on-year growth — revenue +14.3%, earnings +17.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.4%, profit CAGR 14.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.39% |
| 1 Year: | 14.30% |
Compounded Profit Growth
| 5 Years: | 14.82% |
| 1 Year: | 17.20% |
Stock Price Performance
| 1 Year: | +1.74% |
| 6 Months: | -24.21% |
| 3 Months: | -5.80% |
| 1 Month: | -3.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.18 · Neutral
P/E of 39.84 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 72.9%.
- Healthy ROCE of 61.8%.
- Excellent profit margin of 24.6%.
- Profit CAGR of 14.8% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 29.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IDXX IDEXX Laboratories, Inc. NDXSPX | 540.68 | 39.84 | $42.65B | 0.00% | 61.76% | 72.91% | 9.39% | 14.82% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 462.02M | 508.94M | 491.98M | 506.12M | 537.66M | 580.75M | 545.45M | 549.39M | 576.06M | 620.10M | 605.30M | 605.45M | 626.34M | 637.59M | 721.79M | 777.71M | 826.14M | 810.42M | 836.55M | 860.55M | 841.66M | 900.20M | 943.63M | 915.53M | 964.10M | 1.00B | 975.54M | 998.43M | 1.11B | 1.11B | 1.09B | 1.14B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.05M | 414.73M | 421.88M | 432.46M | 418.08M |
| Gross Profit | 215.54M | 232.76M | 224.27M | 217.69M | 227.54M | 260.54M | 246.73M | 240.63M | 258.19M | 292.71M | 274.00M | 272.47M | 303.10M | 332.44M | 305.64M | 300.36M | 331.60M | 357.85M | 344.95M | 331.15M | 359.59M | 379.34M | 422.61M | 470.78M | 489.31M | 472.92M | 498.75M | 514.03M | 506.63M | 542.97M | 572.85M | 547.98M | 593.07M | 619.16M | 596.04M | 623.38M | 694.73M | 683.35M | 658.11M | 722.74M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 306.85M | 321.69M | 328.51M | 342.51M | 360.15M |
| Operating Income | 72.80M | 88.30M | 71.89M | 66.91M | 73.79M | 104.16M | 88.46M | 83.83M | 92.24M | 122.56M | 100.41M | 97.81M | 113.04M | 145.59M | 117.35M | 115.35M | 133.14M | 164.28M | 139.80M | 115.63M | 144.32M | 193.25M | 171.86M | 247.62M | 259.25M | 225.96M | 248.34M | 179.07M | 244.83M | 280.40M | 296.14M | 275.28M | 298.96M | 263.80M | 303.89M | 316.53M | 373.05M | 354.85M | 315.61M | 362.59M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 351.81M | 409.44M | 392.05M | 354.91M | 400.87M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.67M | 11.32M | 10.65M | 9.21M | 7.74M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 310.08M | 362.35M | 344.77M | 306.98M | 355.44M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 67.41M | 68.36M | 70.16M | 58.79M | 77.00M |
| Net Income | 46.59M | 56.91M | 44.22M | 44.35M | 46.02M | 67.20M | 56.45M | 52.37M | 69.02M | 85.36M | 70.51M | 38.26M | 89.45M | 108.69M | 93.25M | 85.64M | 102.68M | 125.71M | 108.84M | 90.50M | 111.83M | 148.94M | 146.22M | 204.26M | 202.58M | 175.24M | 193.97M | 131.98M | 180.94M | 214.05M | 224.24M | 212.23M | 235.58M | 203.30M | 232.84M | 242.68M | 293.99M | 274.61M | 248.19M | 278.45M |
| Diluted EPS | 0.49 | 0.60 | 0.48 | 0.48 | 0.51 | 0.74 | 0.62 | 0.58 | 0.77 | 0.95 | 0.79 | 0.43 | 1.01 | 1.23 | 1.05 | 0.98 | 1.17 | 1.43 | 1.24 | 1.04 | 1.29 | 1.72 | 1.69 | 2.35 | 2.34 | 2.03 | 2.27 | 1.56 | 2.15 | 2.55 | 2.67 | 2.53 | 2.81 | 2.44 | 2.80 | 2.96 | 3.63 | 3.40 | 3.08 | 3.47 |
| R&D Expense | 25.01M | 24.32M | 24.86M | - | 24.62M | 25.41M | 25.67M | - | 25.79M | 27.00M | 27.59M | - | 29.02M | 29.51M | 29.19M | - | 31.51M | 32.26M | 34.26M | - | 33.31M | 31.64M | 37.52M | 37.58M | 37.70M | 40.43M | 40.17M | 123.22M | 48.01M | 44.67M | 46.51M | 47.97M | 52.63M | 55.45M | 53.98M | 59.06M | 61.90M | 63.41M | - | 65.79M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02B | 1.03B | 1.10B | 1.22B | 1.29B | 1.38B | 1.49B | 1.60B | 1.78B | 1.97B | 2.21B | 2.41B | 2.71B | - | 3.37B | 3.66B | 3.90B | 4.30B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.36B | 1.47B | 1.52B | 1.64B |
| Gross Profit | 529.77M | 526.28M | 578.62M | 646.51M | 699.15M | 756.12M | 816.12M | 890.27M | 975.44M | 1.10B | 1.24B | 1.37B | 1.57B | - | 2.00B | 2.19B | 2.38B | 2.66B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.11B | 1.09B | 1.25B | 1.30B |
| Operating Income | 172.46M | 175.97M | 203.88M | 236.22M | 262.56M | 266.76M | 260.25M | 299.91M | 350.24M | 413.03M | 491.33M | 552.85M | 694.52M | - | 898.76M | 1.10B | 1.13B | 1.36B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01B | 1.22B | 1.27B | 1.51B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.86M | 41.58M | 31.20M | 38.85M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 859.97M | 1.06B | 1.11B | 1.32B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 180.88M | 216.13M | 221.96M | 264.73M |
| Net Income | 116.17M | 122.22M | 141.28M | 161.79M | 178.27M | 187.80M | 181.91M | 192.08M | 222.04M | 263.14M | 377.03M | 427.72M | 581.78M | - | 679.09M | 845.04M | 887.87M | 1.06B |
| Diluted EPS | 1.87 | 2.01 | 2.37 | 2.78 | 3.17 | 1.74 | 1.79 | 2.05 | 2.44 | 2.94 | 4.26 | 4.89 | 6.71 | - | 8.03 | 10.06 | 10.67 | 13.08 |
| R&D Expense | 70.67M | 65.12M | 68.60M | 76.04M | 82.01M | 88.00M | 98.26M | 99.68M | 101.12M | 109.18M | 117.86M | 133.19M | 141.25M | 161.01M | 254.82M | 190.95M | 219.79M | 251.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Jan 2018 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 808.53M | 897.14M | 1.03B | 1.10B | 1.23B | 1.38B | 1.47B | 1.53B | 1.71B | 1.74B | 1.54B | 1.62B | 1.83B | 2.29B | 2.44B | 2.75B | 3.26B | 3.29B | 3.35B |
| Total Equity | 438.32M | 438.19M | 514.57M | 574.24M | 539.58M | 636.22M | 518.19M | 117.52M | -84.12M | -108.35M | -54.11M | - | -9.51M | - | 177.47M | 632.09M | 689.99M | 608.74M | 1.48B | 1.60B | 1.61B |
| Cash & Equivalents | 60.36M | 78.87M | 106.73M | 156.91M | 183.90M | 223.99M | 279.06M | 322.54M | 128.99M | 154.90M | 187.68M | - | 123.79M | - | 90.33M | 383.93M | 144.45M | 112.55M | 453.93M | 288.27M | 180.07M |
| Long Term Debt | - | - | - | - | 3.42M | 2.50M | 151.39M | 350.00M | 597.10M | 593.70M | 606.60M | - | 601.80M | - | 698.91M | 858.49M | 775.21M | 694.39M | 622.88M | 449.79M | 374.84M |
| Total Liabilities | - | - | 293.95M | 322.86M | 491.22M | 467.35M | 712.30M | 1.27B | 1.56B | 1.64B | 1.77B | 1.80B | 1.55B | 1.63B | 1.65B | 1.66B | 1.75B | 2.14B | 1.78B | 1.70B | 1.75B |
| Current Liabilities | - | - | 256.31M | 285.11M | 436.88M | 406.33M | 478.35M | 820.91M | 856.76M | 934.57M | 1.00B | - | 770.44M | 784.22M | 725.34M | 582.76M | 763.58M | 1.24B | 951.55M | 1.07B | 1.15B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 143.31M | 174.95M | 178.83M | 217.91M | 222.41M | 246.00M | 235.85M | - | - | 373.28M | 400.08M | 459.16M | 648.06M | 755.55M | 542.98M | 906.51M | 929.00M | 1.18B |
| Investing Cash Flow | -91.59M | -53.62M | -43.19M | -94.21M | -58.13M | -86.06M | -80.41M | - | - | -138.69M | 138.60M | -205.53M | -109.38M | -292.97M | -195.35M | -125.25M | -207.06M | -136.24M |
| Financing Cash Flow | -30.79M | -95.30M | -86.77M | -97.66M | -125.34M | -102.45M | -103.44M | - | - | -208.02M | -597.80M | -286.41M | -248.42M | -697.41M | -370.94M | -442.00M | -878.07M | -1.16B |
| Capital Expenditure | -89.97M | -50.66M | -38.91M | -49.68M | -57.62M | -77.61M | -60.52M | -82.92M | -64.79M | -74.38M | -115.75M | -154.97M | -106.96M | -119.55M | -148.84M | -133.63M | -120.92M | -124.68M |
| Free Cash Flow | 53.34M | 124.29M | 139.93M | 168.24M | 164.79M | 168.38M | 175.32M | - | - | 298.89M | 284.33M | 304.19M | 541.11M | 636.00M | 394.15M | 772.88M | 808.08M | 1.06B |
| Share Buybacks | 132.34M | 83.10M | 143.09M | 255.50M | 132.27M | 367.76M | 618.16M | 401.98M | 304.09M | 282.56M | 369.32M | 301.66M | 182.81M | 746.78M | 819.71M | 71.92M | 837.03M | 1.22B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 51.7% | 51.0% | 52.4% | 53.0% | 54.1% | 54.9% | 54.9% | 55.6% | 54.9% | 55.7% | 56.1% | 56.7% | 58.0% | - | 59.5% | 59.8% | 61.0% | 61.8% |
| Operating Margin % | 16.8% | 17.1% | 18.5% | 19.4% | 20.3% | 19.4% | 17.5% | 18.7% | 19.7% | 21.0% | 22.2% | 23.0% | 25.7% | - | 26.7% | 30.0% | 29.0% | 31.6% |
| Net Margin % | 11.3% | 11.8% | 12.8% | 13.3% | 13.8% | 13.6% | 12.2% | 12.0% | 12.5% | 13.4% | 17.0% | 17.8% | 21.5% | - | 20.2% | 23.1% | 22.8% | 24.6% |
| ROE % | 26.5% | 23.8% | 24.6% | 30.0% | 28.0% | 36.2% | 154.8% | -228.3% | -204.9% | -486.3% | -3,963.3% | 241.0% | 92.0% | - | 111.6% | 56.9% | 55.7% | 66.0% |
| ROCE % | - | 31.9% | 33.3% | 39.8% | 37.7% | 35.5% | 46.2% | 48.5% | 58.8% | 58.3% | 64.1% | 49.9% | 40.6% | - | 59.5% | 47.5% | 50.7% | 61.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.61% | 8.37M | $4.67B |
| 2 | Vanguard Capital Management LLC | 6.57% | 5.18M | $2.89B |
| 3 | Vanguard Portfolio Management LLC | 4.96% | 3.91M | $2.18B |
| 4 | State Street Corporation | 4.66% | 3.67M | $2.05B |
| 5 | Geode Capital Management, LLC | 3.37% | 2.66M | $1.48B |
| 6 | Invesco Ltd. | 2.13% | 1.68M | $936.31M |
| 7 | BAMCO Inc. | 2.07% | 1.63M | $911.10M |
| 8 | Bank Of New York Mellon Corporation | 1.91% | 1.50M | $839.24M |
| 9 | Fundsmith LLP | 1.86% | 1.47M | $817.62M |
| 10 | Morgan Stanley | 1.67% | 1.32M | $734.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IDXX
Why IDEXX Laboratories (IDXX) Stock Is Down Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQdmJoS19wZjJmTXl6UURNQlc4RWl3OVdXSXdteWtoV1haRW5tUkxJbzRXVkU2Wm9JdEtKSUpxc2J0SDJJaTF3NDNYeExITE1NM0RINlotOHZqMEFUMVNNMXZ4czg0RzRJaDRzekpuQmRrT3VPbzlhaHppa0tQWS16SEkxUzZiV2pQTEZITj…
Is IDEXX Laboratories Inc (IDXX) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOajVkdXFHUGY4ZjFVSDd1RktfVXpQbFpuV1ozdmh0NTJCdzk3TmlrM245MnpYb2tYR0ZocUR2cURvdzgwcGwtbGF0S3RDbXRNN29nZmc3THFTaHVFR2ZDWGhpRTBPc0ExV2dDSUpmQjM3S2tZUmxqakluc2hpeUV1NGRCZXlvY3NNRG5kRG…
IDEXX Laboratories Earnings Preview: What to Expect - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNWkptN0EtNzRmN3lTMy1DRDlLWmRXWDlQMFpiTkRwbXN2SUFkekNlWUhVV1Bwa3M2UHlGazdSZ25IOFNpT19mcjFOZEhDQ2p3TnNHS3FreW0tME1RaElFbS1HX1p6TGtKQ2w2aTlWZkNBUk05VXF2MGJLX2hKelFxU0F1aW9GZVpiUFdpRm…
Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15 - TIKR.com
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQRUt2Y2VYekdTT0pqcHRfak82dFE4SGlIcXc0YXJacGdBenhIa2V1VTdOMnRnZnoxbG1aeUZRcVREUnhKUjY0Y09MMDdRbTM0VkFDeVFpMndYVEtBb2ZwY2ZXWTN0ZFZxb0JsNVpkdkRoMkRuM01JSTZZTXU1Vm5XblVwaDN1a0t5YW1Wdj…
IDEXX lines up Aug. 4 earnings call and Aug. 13 Investor Day - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQc1hhSWR0QUdNUVFnajA0RkV3X1NkVEFTdDdMSFJUdzFyLWItbFN1d0RNS2QwR1NLNDY0TnF4cGpZdTFZblQzbjFfVUkzNTQyTjVwSE1VNEFIXzJ2ckNwNEhLU2xzQTN2NHZSajFhaTd1NjBIZDVpd0lndzlsa25YajNFdlRrM3JjeVZPbX…
Why IDEXX Laboratories (IDXX) Could Be 22% Undervalued After Russell Index Additions - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxONlpFaU5VbkR3UVRrMUtRRDAwdnhRN3ZiMG1MQzlpUWVvUFBEdGRCVF9IM0FWM3pIQmdUelMwYVFtVmNxVllLMkNMSmhOUHRHd2ZfZjFjbEhjNEE2Z1VCMkxmaXlPeElMWlZNcjAxdC13T1B3YjVaZzdYSE8ybWpJRjdHTVBfRThrb2V1NU…
IDXX — Frequently Asked Questions
What is the current share price of IDEXX Laboratories, Inc. (IDXX)?
As of 2026-07-14 21:23 PDT, IDEXX Laboratories, Inc. (IDXX) trades at $540.68 on NasdaqGS. Its 52-week range is $514.61 to $766.68.
What is the market capitalisation of IDXX?
IDEXX Laboratories, Inc. (IDXX) has a market capitalisation of $42.65B on NasdaqGS.
What is the P/E ratio of IDXX?
IDXX trades at a trailing price-to-earnings (P/E) ratio of 39.84. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 28.56.
What is the return on equity (ROE) of IDXX?
IDXX has a return on equity (ROE) of 72.91%. Its return on capital employed (ROCE) is 61.76%.
Is IDXX a good stock to buy?
This page provides a data-driven analysis of IDEXX Laboratories, Inc. (IDXX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.